Marie-Hélène Lafeuille

Montreal
Education
M.A. and B.A., economics, Université de Sherbrooke
Summary of Experience
Ms. Lafeuille specializes in health economics and outcomes research. She has conducted a wide range of analyses for the investigation of, among other topics, clinical efficacy, safety profile, cost of illness, resource utilization patterns, treatment patterns, and cost-effectiveness in a broad range of disease areas, including oncology, hematology, schizophrenia, asthma, diabetes mellitus, epilepsy, chronic kidney disease, and cardiovascular diseases. Ms. Lafeuille has extensive experience performing retrospective insurance claims database analyses, retrospective electronic medical record and chart review studies, clinical trial data analyses, and systematic literature reviews (including meta-analyses). Her research has been presented at numerous international clinical conferences, and she has published on various health economic topics, including treatment patterns, direct and indirect resource utilization and medical costs, and drug cost-effectiveness, in several peer-reviewed journals, including Neurology, Hypertension, Cancer, and Menopause. Ms. Lafeuille is a member of the International Society of Pharmacoeconomics and Outcomes Research.
Selected Publishing
-
CLL-492 Real-World Adherence to First-Line Ibrutinib and Acalabrutinib Single-Agent Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Clinical Lymphoma, Myeloma & Leukemia, 2022
2022Lu X, Emond B, Qureshi Z, He J, Qian Y, Huang Q, Lefebvre P, Lafeuille MH, Jacobs R
-
Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax
Current Medical Research and Opinion, 2021
2021Rogers KA, Emond B, Manceur AM, Kinkead F, Lafeuille MH, Lefebvre P, Huang Q
-
Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational Study
Drugs - Real World Outcomes, 2021
2021Gordan L, Chang M, Lafeuille MH, Romdhani H, Paramasivam F, Maiese EM, McKay C
-
Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE clinical trial
Current Medical Research and Opinion, 2020
2020Manceur AM, Durkin M, Kharat A, Bookhart B, Lafeuille MH, Pilon D, Fakih I, Lefebvre P
-
Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs
Journal of Medical Economics, 2020
2020Manceur AM, Ding Z, Muser E, Obando C, Voelker J, Pilon D, Kinkead F, Lafeuille MH, Lefebvre P
-
Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database
Dermatology and Therapy, 2020
2020Eichenfield LF, DiBonaventura M, Xenakis J, Lafeuille MH, Duh MS, Fakih I, Levenberg M, Cappelleri JC, Sikirica V
-
An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus
Current Medical Research and Opinion, 2020
2020Chow W, Donga P, Côté-Sergent A, Rossi C, Lefebvre P, Lafeuille MH, Emond B, Hardy H
-
Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
Drugs - Real World Outcomes, 2020
2020Patel C, Emond B, Lafeuille MH, Côté-Sergent A, Lefebvre P, Tandon N, El Khoury AC
-
Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
Patient Preference and Adherence, 2020
2020Chow W, Donga P, Côté-Sergent A, Rossi C, Lefebvre P, Lafeuille MH, Hardy H, Emond B
-
Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia
Current Medical Research and Opinion, 2020
2020Huang Q, Emond B, Lafeuille MH, Gupta D, Lefebvre P, Sundaram M, Mato A
-
An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records
Journal of Diabetes and its Complications, 2019
2019Wysham CH, Lefebvre P, Pilon D, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Duh MS, Ingham M
-
Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials
Journal of Medical Economics, 2019
2019Kamstra R, Durkin M, Cai J, Bookhart B, Lafeuille MH, Pilon D, Tiggelaar S, Manceur AM, Lefebvre P
-
Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate
PharmacoEconomics - Open, 2019
2019Emond B, Joshi K, El Khoury AC, Lafeuille MH, Pilon D, Tandon N, Romdhani H, Lefebvre P
-
Real-world impact of glycated hemoglobin reduction on treatment intensification and glycated hemoglobin goal attainment in type 2 diabetes mellitus patients initiated on a sodium glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i)
Current Medical Research and Opinion, 2019
2019Brunton S, Rozjabek HM, Pilon D, Lafeuille MH, Kamstra R, Wynant W, Bookhart BK, Lefebvre P
-
Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage
Journal of Managed Care & Specialty Pharmacy, 2019
2019Benson C, Emond B, Lefebvre P, Lafeuille MH, Côté-Sergent A, Tandon N, Chow W, Dunn K
-
Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma
Clinical Therapeutics, 2019
2019Ailawadhi S, DerSarkissian M, Duh MS, Lafeuille MH, Posner G, Ralston S, Zagadailov E, Ba-Mancini A, Rifkin R
-
Hba1c control and cost-effectiveness in patients with type 2 diabetes mellitus initiated on canagliflozin or a glucagon-like peptide 1 receptor agonist in a real-world setting
Endocrine Practice. 03 2018;24(3):273-287
2018Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P
-
Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting
Current Medical Research and Opinion. 2018 Jun;34(6):1125-1133
2018Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P
-
Economic burden of treatment failure in chronic lymphocytic leukemia patients
Current Medical Research and Opinion. 2018 Jun;34(6):1135-1142
2018Wang S, Lafeuille MH, Lefebvre P, Romdhani H, Emond B, Senbetta M
-
Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin
Current Medical Research and Opinion. 2018 Jun;34(6):1099-1115
2018Tanton D, Duh MS, Lafeuille MH, Lefebvre P, Pilon D, Zhdanava M, Emond B, Inman D, Bailey RA
-
Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data
Cardiovascular Diabetology. Aug 24 2018;17(1):118
2018Young JB, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Lafeuille MH, Duh MS, Bookhart B, Wysham CH
-
Burden of disease associated with a COPD eosinophilic phenotype
International Journal of Chronic Obstructive Pulmonary Disease. 2018 Aug 13;13:2425-2433
2018Ortega H, Llanos JP, Lafeuille MH, Germain G, Duh MS, Bell CF, Sama SR, Hahn B
-
Effects of Systemic Corticosteroids on Blood Eosinophil Counts in Asthma: Real-World Data
Journal of Asthma. 2018 Oct 16:1-8
2018Ortega H, Llanos JP, Lafeuille MH, Duh MS, Germain G, Lejeune D, Sama S, Bell C, Hahn B
-
Health characteristics of patients with asthma, COPD and asthma-COPD overlap in the NHANES database
International Journal of Chronic Obstructive Pulmonary Disease. 2018 Sep 12;13:2859-2868
2018Llanos JP, Ortega H, Germain G, Duh MS, Lafeuille MH, Tiggelaar S, Bell CF, Hahn B
-
Risk Factors, Health Care Resource Utilization, and Costs Associated with Nonadherence to Antiretrovirals in Medicaid-Insured Patients with HIV
Journal of Managed Care & Specialty Pharmacy. 2018 Oct;24(10):1040-1051
2018Dunn K, Lafeuille MH, Jiao X, Romdhani H, Emond B, Woodruff K, Pesa J, Tandon N, Lefebvre P
-
Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans
Clinical Therapeutics. 2018 Sep;40(9):1496-1508
2018DerSarkissian M, Lefebvre P, Joshi K, Brown B, Lafeuille MH, Bhak RH, Hellstern M, Bobbili P, Shiner B, El Khoury AC, Young-Xu Y
-
Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting
Current Medical Research and Opinion. Oct 2017;33(10):1763-1772
2017Joshi K, Lafeuille MH, Brown B, Wynant W, Emond B, Lefebvre P, Tandon N
-
Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program
Current Medical Research and Opinion. Apr 2017;33(4):713-721
2017Pilon D, Amos TB, Germain G, Lafeuille MH, Lefebvre P, Benson CJ
-
Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors
BMC Endocrine Disorders. Jun 08 2017;17(1):32
2017Wysham CH, Lefebvre P, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Chow W, Pfeifer M, Duh MS
-
Burden of systemic glucocorticoid-related complications in severe asthma(1)
Current Medical Research and Opinion. Jan 2017;33(1):57-65
2017Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA
-
Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics
Clinical Therapeutics. Oct 2017;39(10):1972-1985 e1972
2017Pilon D, Tandon N, Lafeuille MH, Kamstra R, Emond B, Lefebvre P, Joshi K
-
Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology
Leukemia and Lymphoma. Aug 2017;58(8):1968-1972
2017Skarbnik AP, Ma E, Lafeuille MH, Fortier J, Feldman T, Duh MS, van de Velde H, Niculescu L, Bonthapally V, Goy A
-
Burden of systemic glucocorticoid-related complications in severe asthma
Current Medical Research and Opinion, 2016 Oct 14:1-29
2016Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA.
-
Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics
Current Medical Research and Opinion, 2016 04; 32(4): 759-769. e-pub ahead of print 2016/01/12
2016Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P.
-
Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.
Current Medical Research and Opinion, Opin 2016 06; 32(6): 1151-1159. e-pub ahead of print 2016/04/27
2016Lefebvre P, Pilon D, Robitaille MN, Lafeuille MH, Chow W, Pfeifer M, Duh MS.
-
Opportunities for Improving Attainment of Quality Measures in Patients With Type 2 Diabetes Mellitus
American Journal of Managed Care, Volume 20, Number 1, Supplement - January 2014
2014Bailey R, Blonde L, Damaraju CV, Duh MS, Garber L, Gravel J, Grittner A, Lafeuille M, Lefebvre P, Martin S, Meininger G, Rupnow M
-
Incremental direct and indirect costs of untreated vasomotor symptoms
Menopause, August 25, 2014
2014Sarrel P, Portman D, Lefebvre P, Lafeuille M, Grittner A, Fortier J, Gravel J, Duh MS, Aupperle P
-
Quality measure attainment in patients with type 2 diabetes mellitus
The American Journal of Managed Care, 2014
2014Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P
-
Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia
Leuk Lymphoma. 2011 Nov 23
2011Lafeuille M, Vekeman F, Wang S, Kerrigan M, Menditto L, Duh MS
-
Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings
J Med Econ. 2011 Dec 14.
2011Lafeuille M, Bailey R, Vekeman F, Scott McKenzie R, Lefebvre P
-
Risk of Hepatotoxicity-Related Hospitalizations Among Patients Treated With Opioid-Acetaminophen Combination Prescription Pain Medications
Pain Med. 2010 Nov;11(11):1718-25
2010Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Viau-Latremouille D, Stangle B, Lafeuille M, Greenberg P
-
Generic antiepileptic drugs and associated medical resource utilization in the United States
Neurology 2010 74: 1566-1574
2010Labiner D, Paradis P, Manjunath R, Duh MS, Lafeuille M, Latremouille-Viau D, Lefebvre P, Helmers S
-
Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease
The Consultant Pharmacist, 2010
2010Lafeuille MH, Bailey RA, Vekeman F, Kilpatrick BS, Senbetta M, Piech CT, Lefebvre P
-
Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries
Curr Med Res Opin. 2009; 25(7):1793-1805
2009Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille M, Lefebvre P, Gaudig M, Duh MS
News
-
December 7, 2022
-
March 29, 2022
-
October 15, 2021
-
June 4, 2021